Seaport Therapeutics SPTX Increase Decrease In Accrued Expenses And Other Current Liabilities
Other financials
Where this comes from
Reported directly by Seaport Therapeutics in its filing.
Tagged under the XBRL concept sptx:IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities.
The official record: Seaport Therapeutics ’s 10-Q, filed June 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Seaport Therapeutics 's increase decrease in accrued expenses and other current liabilities.
Connect your AI assistant and see it in context, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Seaport Therapeutics 's increase decrease in accrued expenses and other current liabilities?
- Seaport Therapeutics (SPTX) reported increase decrease in accrued expenses and other current liabilities of -$1.5M in Q1 2026.